

**AUDITOR'S REPORT**

TO  
THE MEMBERS OF SAI LIFE SCIENCES INC.

**Report on the Financial Statements**

We have audited the accompanying financial statements of SAI LIFE SCIENCES INC, ('the Company'), which comprise the Balance Sheet as at 31st March 2022, the statement of Profit and Loss and the cash flow statement for the year then ended, and a summary of significant accounting policies and other explanatory information. The financial statements are in US\$ and are converted into Indian INR based on the conversion rate applicable. Sai Life Sciences Inc., USA is a subsidiary of Sai Life Sciences Ltd., India

**Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

**Auditor's Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. We have taken into account the provisions of the Companies Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made there under. We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.



An Audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Ind AS financial statements. The procedures selected depend upon the Auditor's judgment, including the assessment of the risks of material misstatement of the financial statement, whether due to fraud or error.

In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Ind AS financial statements in order to design audit procedures that appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Opinion**


In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind As financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India.

- a) In the case of the Balance Sheet, of the state of affairs of the Company as at 31<sup>st</sup> March 2022
- b) In the case of the statement of Profit and Loss, of the profit for the year ended on 31st March 2022.

### **Report on Other Legal and Regulatory Requirements**

As required by Section 143 (3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
- c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on 31st March 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2022 from being appointed as a director in terms of Section 164 (2) of the Act.




f) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company does not have any pending litigations which would impact its financial position
- ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company

For SIVA KRISHNA & NARAYANAN  
CHARTERED ACCOUNTANTS  
Firm Reg No. 003883S

UDIN: 22206635AOXHZZH4673

R V N Sastry,  
Partner  
M.No.206635



Place: Hyderabad,

Date: 12.08.2022.

Sai Life Sciences Inc  
Balance Sheet as at 31 March 2022

	Note	As at			
		31 March 2022		31 March 2021	
		USD	INR (Lakhs)	USD	INR (Lakhs)
<b>ASSETS</b>					
<b>Non-current assets</b>					
(a) Property, plant and equipment	3	49,08,817.24	3,720.52	39,95,532.28	2,921.13
(b) Capital work in progress		-	-	2,11,069.26	154.31
(c) Right to use Assets	4	86,30,855.09	6,541.54	12,06,486.25	882.06
(d) Intangible assets	4	1,70,095.13	128.92	2,12,245.55	155.17
(e) Other non-current assets		7,21,777.54	570.60	3,33,288.58	278.63
<b>Total non-current assets</b>		<b>1,44,31,545.00</b>	<b>10,961.58</b>	<b>59,58,621.92</b>	<b>4,391.30</b>
<b>Current assets</b>					
(a) Financial assets					
(i) Trade receivables	6	17,13,206.09	1,298.48	18,29,938.13	1,337.87
(ii) Cash and cash equivalents	7	8,72,183.12	661.05	8,56,261.72	626.01
(b) Other current assets	5	4,51,678.24	342.34	7,87,844.32	575.99
<b>Total current assets</b>		<b>30,37,067.45</b>	<b>2,301.87</b>	<b>34,74,044.17</b>	<b>2,539.87</b>
<b>Total assets</b>		<b>1,74,68,612.45</b>	<b>13,263.45</b>	<b>94,32,666.09</b>	<b>6,931.17</b>
<b>EQUITY AND LIABILITIES</b>					
<b>Equity</b>					
(a) Equity share capital	8	1,39,849.00	102.10	1,39,849.00	102.10
(b) Other equity	9	50,46,002.72	3,897.20	62,98,143.24	4,639.67
<b>Total equity</b>		<b>51,85,851.72</b>	<b>3,999.29</b>	<b>64,37,992.24</b>	<b>4,741.77</b>
<b>Liabilities</b>					
<b>Non-current liabilities</b>					
(a) Financial liabilities					
(i) Lease Liabilities		84,69,723.14	6,419.41	10,15,596.36	742.50
<b>Total non-current liabilities</b>		<b>84,69,723.14</b>	<b>6,419.41</b>	<b>10,15,596.36</b>	<b>742.50</b>
<b>Current liabilities</b>					
(a) Financial liabilities					
(i) Trade payables	12	15,40,155.13	1,167.33	5,43,336.68	397.23
(ii) Other financial liabilities	10	15,586.45	11.81	8,41,298.32	615.07
(b) Provisions	12	-	-	-	-
(b) Income tax liabilities (net)	13	-	-	-	-
(c) Other current liabilities	11	22,57,296.01	1,665.60	5,94,442.49	434.60
<b>Total current liabilities</b>		<b>38,13,037.59</b>	<b>2,844.74</b>	<b>19,79,077.49</b>	<b>1,446.90</b>
<b>Total equity and liabilities</b>		<b>1,74,68,612.45</b>	<b>13,263.45</b>	<b>94,32,666.09</b>	<b>6,931.17</b>
Significant accounting policies	1				
Notes to the Ind AS financial statements	2				


The notes referred to above form an integral part of the Ind AS financial statements.

As per our Report on Ind AS financial statements of even date attached

For SIVA KRISHNA & NARAYAN  
Chartered Accountants  
Firm's Registration Number: 003883S

For and on behalf of the Board of Directors of  
Sai Life Sciences Inc

R.V.N. SASTRY  
Partner  
Membership No.: 206635



*Krishna Raju*  
Krishna Raju  
Director

Place: Hyderabad  
Date: 12 August, 2022

Place: Hyderabad  
Date: 12 August, 2022

Sai Life Sciences Inc  
Statement of Profit and Loss for the year ended 31 March 2022


	Note	For the year ended			
		31 March 2022		31 March 2021	
		USD	INR (Lakhs)	USD	INR (Lakhs)
Revenue from operations	14	99,83,445.94	7,440.70	72,03,101.06	5,346.64
<b>Total income</b>		<b>99,83,445.94</b>	<b>7,440.70</b>	<b>72,03,101.06</b>	<b>5,346.64</b>
<b>Expenses</b>					
Cost of materials consumed	15	19,52,115.87	1,454.45	3,43,051.72	254.64
Employee benefits expense	16	50,09,822.42	3,732.63	37,68,811.05	2,797.47
Finance costs		4,65,417.44	346.77	1,31,926.51	97.92
Depreciation and amortisation expense	17	14,16,664.60	1,055.50	10,50,914.22	780.06
Other expenses	18	28,31,507.40	2,109.39	26,59,737.95	1,974.24
<b>Total expenses</b>		<b>1,16,75,527.73</b>	<b>8,698.74</b>	<b>79,54,441.45</b>	<b>5,904.34</b>
<b>Profit before tax</b>		<b>(16,92,081.79)</b>	<b>(1,258.04)</b>	<b>(7,51,340.39)</b>	<b>(557.70)</b>
Tax expense	19				
Current tax		(4,39,941.27)	(327.09)	(1,96,522.45)	(145.87)
Total tax expenses		<b>(4,39,941.27)</b>	<b>(327.09)</b>	<b>(1,96,522.45)</b>	<b>(145.87)</b>
<b>Profit for the year</b>		<b>(12,52,140.52)</b>	<b>(930.95)</b>	<b>(5,54,817.94)</b>	<b>(411.83)</b>
<b>Other comprehensive income</b>					
<b>Items that will not be reclassified subsequently to profit or loss:</b>					
(a) Re-measurement gains/(losses) of defined benefit plans		-	-	-	-
(b) Income-tax on items that will not be reclassified to profit or loss		-	-	-	-
Total other comprehensive income for the year, net of tax		-	-	-	-
<b>Total comprehensive income for the year</b>		<b>(12,52,140.52)</b>	<b>(930.95)</b>	<b>(5,54,817.94)</b>	<b>(411.83)</b>

Significant accounting policies	1
Notes to the Ind AS financial statements	2

The notes referred to above form an integral part of the Ind AS financial statements.  
As per our Report on Ind AS financial statements of even date attached

For SIVA KRISHNA & NARAYAN  
Chartered Accountants  
Firm's Registration Number: 003883S

R.V.N. SASTRY  
Partner  
Membership No.: 206635



Place: Hyderabad  
Date: 12 August, 2022

For and on behalf of the Board of Directors of  
Sai Life Sciences Inc

Krishna Raju  
Director

Place: Hyderabad  
Date: 12 August, 2022

Sai Life Sciences Inc

Standalone Statement of Cash Flows for the year ended 31 March 2022

(All amounts in Indian Rupees lakhs, except share data and where otherwise stated)

	For the year ended			
	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
<b>Cash flow from operating activities</b>				
Profit before tax	(16,92,081.79)	(1,258.04)	(7,51,340.39)	(557.70)
<b>Adjustments for :</b>				
Depreciation and amortisation expense	14,16,664.60	1,055.50	10,50,914.22	780.06
Finance Costs	4,65,417.44	346.77	-	-
<b>Operating cash flows before working capital changes</b>	<b>1,90,000.25</b>	<b>144.23</b>	<b>2,99,573.83</b>	<b>222.36</b>
Increase in trade receivables	1,16,732.04	39.39	(17,95,185.98)	(1,311.57)
Increase in other current assets	3,36,166.08	233.65	(4,53,189.39)	(322.75)
Increase in other non current assets	(3,88,488.96)	(291.97)	(1,57,829.00)	(145.87)
Increase/(decrease) in trade payables	9,96,818.43	770.09	13,287.32	(3.83)
Increase in other financial liabilities & provisions	(8,25,711.87)	(414.78)	5,70,420.01	335.92
(Decrease)/increase in other non-current and current liabilities	91,16,980.97	6,908.22	1,53,976.54	101.32
<b>Cash generated from operating activities</b>	<b>95,42,496.93</b>	<b>7,388.82</b>	<b>(13,68,946.67)</b>	<b>(1,124.42)</b>
Income-taxes paid, net	4,39,941.27	327.09	1,96,522.45	145.87
<b>Net cash generated from operating activities (A)</b>	<b>99,82,438.20</b>	<b>7,715.91</b>	<b>(11,72,424.22)</b>	<b>(978.55)</b>
<b>Cash flows from investing activities</b>				
intangible assets ( including capital work in progress, capital advances and capital creditors)	(95,79,129.32)	(7,265.92)	(27,53,602.79)	(1,925.20)
Proceeds from sale of property, plant and equipment	-	-	-	-
Movement in other bank balances, net	-	-	-	-
Interest income received	-	-	-	-
<b>Net cash used in investing activities (B)</b>	<b>(95,79,129.32)</b>	<b>(7,265.92)</b>	<b>(27,53,602.79)</b>	<b>(1,925.20)</b>
<b>Cash flows from financing activities</b>				
Proceeds from issue of equity shares			54,99,902.00	4,098.18
Lease Payments	(3,87,387.48)	(414.95)	(11,05,647.97)	(862.03)
<b>Net cash generated from financing activities (C)</b>	<b>(3,87,387.48)</b>	<b>(414.95)</b>	<b>43,94,254.03</b>	<b>3,236.15</b>
<b>Net decrease in cash and cash equivalents during the year (A + B + C)</b>	<b>15,921.40</b>	<b>35.04</b>	<b>4,68,227.02</b>	<b>332.40</b>
Effect of exchange differences on cash and cash equivalents held in foreign currency				
Cash and cash equivalents at the beginning of the year	8,56,261.72	626.01	3,88,034.70	293.61
<b>Cash and cash equivalents at the end of the year (Note 1 below)</b>	<b>8,72,183.12</b>	<b>661.05</b>	<b>8,56,261.72</b>	<b>626.01</b>

Sai Life Sciences Inc

Standalone Statement of Cash Flows for the year ended 31 March 2022

(All amounts in Indian Rupees lakhs, except share data and where otherwise stated)

	As at			
	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
<b>Note 1:</b>				
<b>Cash and cash equivalents includes</b>				
Balances with banks				
-in current accounts	8,72,183.12	661.05	8,56,261.72	626.01
	<b>8,72,183.12</b>	<b>661.05</b>	<b>8,56,261.72</b>	<b>626.01</b>

See accompanying notes forming part of these standalone financial statements

For SIVA KRISHNA & NARAYAN

Chartered Accountants

Firm's Registration Number: 003883S

R.V.N. SASTRY

Partner

Membership No.: 206635

Place: Hyderabad

Date: 12 August, 2022



*[Handwritten Signature]*

Krishna Raju

Director

Place: Hyderabad

Date: 12 August, 2022

## Statement of Changes in Equity for the year ended 31 March 2022

A Equity Share Capital (Refer note 8)

	Note	Number of shares	Amount
As at 1 April 2020		19,563	12.76
Changes in equity share capital	8	1,20,286	89
As at 31 March 2021		1,39,849	102.10
Changes in equity share capital	8		
As at 31 March 2022		1,39,849	102.10

B Other Equity (Refer note 8)

	Securities premium reserve	Reserves and Surplus			Retained earnings	Remeasurement of defined benefit obligations	Other comprehensive income Exchange differences on translating the financial statements of foreign operations	Total	Total (USD)
		Share application money pending allotment	Employee stock options outstanding account	Capital reserve					
Balance as at 31 March 2020	1,071.73	-	-	-	(47.46)	-	92.58	1,116.85	14,73,345.18
Profit for the year	-	-	-	-	(411.83)	-	-	(411.83)	(5,54,817.94)
Other comprehensive income - net of tax	-	-	-	-	-	-	-	-	-
Foreign currency translation adjustments	-	-	-	-	-	-	-	-	-
<b>Total comprehensive income</b>	-	-	-	-	(411.83)	-	(74.18)	(486.01)	-
Share application money received	-	-	-	-	-	-	(74.18)	(74.18)	-
Security premium on equity shares	4,008.83	-	-	-	-	-	-	4,008.83	(5,54,817.94)
Share-based payment expense	-	-	-	-	-	-	-	-	-
<b>Balance as at 31 March 2021</b>	<b>5,080.57</b>	-	-	-	<b>(459.29)</b>	-	<b>18.40</b>	<b>4,639.67</b>	<b>62,98,143.24</b>
Profit for the year	-	-	-	-	(930.95)	-	-	(930.95)	(12,52,140.52)
Other comprehensive income - net of tax	-	-	-	-	-	-	-	-	-
Foreign currency translation adjustments	-	-	-	-	-	-	-	-	-
<b>Total comprehensive income</b>	-	-	-	-	(930.95)	-	188.47	188.47	-
Share application money received	-	-	-	-	-	-	188.47	188.47	-
Security premium on equity shares	-	-	-	-	-	-	-	-	-
Share-based payment expense	-	-	-	-	-	-	-	-	-
<b>Balance as at 31 March 2022</b>	<b>5,080.57</b>	-	-	-	<b>(1,390.24)</b>	-	<b>206.87</b>	<b>3,897.20</b>	<b>50,46,002.72</b>

Significant accounting policies

Notes to the Ind AS financial statements

1  
2

The notes referred to above form an integral part of the Ind AS financial statements.

As per our Report on Ind AS financial statements of even date attached

For SIVA KRISHNA & NARAYAN  
Chartered Accountants  
Firm's Registration Number: 0033883S



R.V.N. SASTRY  
Partner  
Membership No.: 206635

Place: Hyderabad  
Date: 12 August, 2022

For and on behalf of the Board of Directors of  
Sai Life Sciences Inc

*Krishna Raju*  
Krishna Raju  
Director

Place: Hyderabad  
Date: 12 August, 2022

## 3. Property, plant and equipment

	Freehold land	Leasehold land	Buildings	Leasehold improvements	Plant and equipment	Furnitures and fixtures*	Freehold Computers	Total	Total (USD)
<b>Cost or deemed cost (gross carrying amount)</b>									
Balance as at 1 April 2020	-	-	-	-	165.12	7.37	0.97	173.46	2,31,087.10
Additions	-	-	-	-	2,761.39	-	31.75	2,793.13	38,27,054.38
Adjustments	-	-	-	-	-	(0.18)	-	(0.18)	-
Disposals/retirement	-	-	-	-	-	-	-	-	-
<b>Balance as at 31 March 2021</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,926.51</b>	<b>7.19</b>	<b>32.72</b>	<b>2,966.41</b>	<b>40,58,141.48</b>
Additions	-	-	-	-	669.12	191.94	95.90	956.96	12,62,601.30
Adjustments	-	-	-	-	(102.26)	0.10	(0.53)	(102.69)	-
Disposals/retirement	-	-	-	-	-	-	-	-	-
<b>Balance as at 31 March 2022</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,697.89</b>	<b>199.03</b>	<b>129.15</b>	<b>4,026.06</b>	<b>53,20,742.78</b>
<b>Accumulated depreciation</b>									
Balance as at 1 April 2020	-	-	-	-	6.92	-	0.91	7.83	12,161.87
Charge for the year	-	-	-	-	29.20	4.50	3.75	37.45	50,447.33
Adjustments	-	-	-	-	-	-	-	-	-
Disposals/retirement	-	-	-	-	-	-	-	-	-
<b>Balance as at 31 March 2021</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>36.12</b>	<b>4.50</b>	<b>4.66</b>	<b>45.28</b>	<b>62,609.20</b>
Charge for the year	-	-	-	-	219.09	11.94	29.23	260.26	3,49,316.34
Adjustments	-	-	-	-	-	-	-	-	-
Disposals/retirement	-	-	-	-	-	-	-	-	-
<b>Balance as at 31 March 2022</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>255.21</b>	<b>16.44</b>	<b>33.89</b>	<b>305.54</b>	<b>4,11,925.54</b>
<b>Net carrying value</b>									
As at 1 April 2020	-	-	-	-	158.20	7.37	0.06	165.63	2,18,925.23
As at 31 March 2021	-	-	-	-	2,890.39	2.69	28.06	2,921.13	39,95,532.28
As at 31 March 2022	-	-	-	-	3,442.69	182.59	95.24	3,720.52	49,08,817.24

CWIP as on 31 March 2022 - Nil (31 March 2021 : \$ 211,069.26)




*[Handwritten Signature]*



Sai life sciences Inc  
Notes forming part of Standalone Financial Statements

4. Right to Use assets

Cost													
Particulars	Leasehold Land	Building	Equipment	Vehicles	Office premises	Computers	Total	INR					
<b>Balance at April 1, 2020</b>	-	16,90,657.86	7,28,278.00	-	-	-	24,18,935.86	1,815.86					
Additions	-	-	-	-	-	-	-	(43.94)					
Disposals/retirement/adjustment	-	-	-	-	-	-	-						
<b>Balance at March 31, 2021</b>	-	<b>16,90,657.86</b>	<b>7,28,278.00</b>	-	-	-	<b>24,18,935.86</b>	<b>1,771.92</b>					
Additions	-	84,85,780.28	41,817.00	-	-	-	85,27,597.28	6,463.28					
Adjustments	-	78,029.96	-	-	-	-	78,029.96	18.17					
Deletions	-	-	-	-	-	-	-	58.13					
<b>Balance as at March 31, 2022</b>	-	<b>1,00,98,408.18</b>	<b>7,70,095.00</b>	-	-	-	<b>1,08,68,503.18</b>	<b>8,195.24</b>					
<b>Accumulated amortization</b>													
Particulars	Leasehold Land	Building	Equipment	Vehicles	Office premises	Computers	Total	INR					
<b>Balance at April 1, 2020</b>	-	2,88,475.89	12,359.04	-	-	-	3,00,834.93	213.19					
Additions	-	8,63,062.84	48,551.84	-	-	-	9,11,614.68	676.66					
Deletions	-	-	-	-	-	-	-						
<b>Balance at March 31, 2021</b>	-	<b>11,51,538.73</b>	<b>60,910.88</b>	-	-	-	<b>12,12,449.61</b>	<b>889.86</b>					
Depreciation expense	-	9,74,682.76	50,515.73	-	-	-	10,25,198.49	763.84					
Deletions	-	-	-	-	-	-	-						
<b>Balance as at March 31, 2022</b>	-	<b>21,26,221.49</b>	<b>1,11,426.61</b>	-	-	-	<b>22,37,648.10</b>	<b>1,653.69</b>					
<b>Balance at March 31, 2021</b>	-	<b>5,39,119.13</b>	<b>6,67,367.12</b>	-	-	-	<b>12,06,486.25</b>	<b>882.06</b>					
<b>Balance as at March 31, 2022</b>	-	<b>79,72,186.70</b>	<b>6,58,668.39</b>	-	-	-	<b>86,30,855.09</b>	<b>6,541.54</b>					



*Handwritten signature*

Sai Life Sciences Inc

Notes to the standalone financial statements for the year ended 31 March 2022 (continued)

(All amounts in Indian Rupees lakhs, except share data and where otherwise stated)

4. Other intangible assets

	Acquired Software	Total INR	Total USD
<b>Cost or deemed cost</b>			
Balance as at 1 April 2020			
Additions	221.12	221.12	3,01,097.50
Disposals/retirement	-	-	-
<b>Balance as at 31 March 2021</b>	<b>221.12</b>	<b>221.12</b>	<b>3,01,097.50</b>
Additions			
Disposals/retirement	-	-	-
<b>Balance as at 31 March 2022</b>	<b>221.12</b>	<b>221.12</b>	<b>3,01,097.50</b>
<b>Accumulated amortization</b>			
Balance as at 1 April 2020	-	-	-
Charge for the year	65.95	65.95	88,851.95
Disposals/retirement	-	-	-
<b>Balance as at 31 March 2021</b>	<b>65.95</b>	<b>65.95</b>	<b>88,851.95</b>
Charge for the year	31.40	31.40	42,150.42
Adjustments	(5.15)	(5.15)	
Disposals/retirement	-	-	-
<b>Balance as at 31 March 2022</b>	<b>92.20</b>	<b>92.20</b>	<b>1,31,002.37</b>
<b>Net carrying amount</b>			
As at 31 March 2021	155.17	155.17	2,12,245.55
As at 31 March 2022	128.92	128.92	1,70,095.13



*Handwritten signature*

5. Other assets

(Unsecured, considered good unless stated otherwise)

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
<b>Current</b>				
Advance Paid	18,912.77	14.33	1,14,819.71	83.94
Balances with statutory authorities	-	-	1,98,907.05	145.42
Work in Progress	1,26,767.10	96.08	4,13,006.50	301.95
Others	3,05,998.37	231.92	61,111.06	44.67
	<b>4,51,678.24</b>	<b>342.34</b>	<b>7,87,844.32</b>	<b>575.99</b>

6. Trade receivables

(Unsecured)

- Considered good  
- Considered doubtful

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
	17,13,206.09	1,298.48	18,29,938.13	1,337.87
	-	-	-	-
	<b>17,13,206.09</b>	<b>1,298.48</b>	<b>18,29,938.13</b>	<b>1,337.87</b>
	-	-	-	-
	<b>17,13,206.09</b>	<b>1,298.48</b>	<b>18,29,938.13</b>	<b>1,337.87</b>

Less: Loss allowance for doubtful debts

Trade receivables Aging:

For the year ended March 31, 2022

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables – considered good	1,260.34	31.56	6.58	-	-	1,298.48
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables - credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables– considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
<b>Total</b>	<b>1,260.34</b>	<b>31.56</b>	<b>6.58</b>	<b>-</b>	<b>-</b>	<b>1,298.48</b>

For the year ended March 31, 2021

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables – considered good	414.16	94.23	762.25	-	67.23	1,337.87
(ii) Undisputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed Trade receivables - credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivables– considered good	-	-	-	-	-	-
(v) Disputed Trade Receivables – which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivables – credit impaired	-	-	-	-	-	-
<b>Total</b>	<b>414.16</b>	<b>94.23</b>	<b>762.25</b>	<b>-</b>	<b>67.23</b>	<b>1,337.87</b>

7. Cash and cash equivalents and other bank balances

(i) Cash and cash equivalents

Cash on hand  
Balances with banks  
-in current accounts  
-in deposit accounts (with maturity of 3 months or less)\*

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
	-	-	-	-
	-	-	-	-
	8,72,183.12	661.05	8,56,261.72	626.01
	-	-	-	-
	<b>8,72,183.12</b>	<b>661.05</b>	<b>8,56,261.72</b>	<b>626.01</b>

(ii) Bank balances other than above

in deposit accounts (due to mature within 12 months but more than 3 months)\*

	-	-	-	-
	-	-	-	-
	<b>8,72,183.12</b>	<b>661.05</b>	<b>8,56,261.72</b>	<b>626.01</b>



*L. K. K. Reddy*

8. Equity share capital

i. Authorised share capital

	31 March 2022		31 March 2021	
	Number	Amount	Number	Amount
1,39,849 (previous year : 19,563) common shares of US\$ 1 each	2,50,000	182.78	2,50,000	182.78

ii. Issued, subscribed and fully paid up

	31 March 2022		31 March 2021	
	Number	Amount	Number	Amount
1,39,849 (previous year : 19,563) common shares of US\$ 1 each	1,39,849	102.10	1,39,849	102.10
	<b>1,39,849</b>	<b>102.10</b>	<b>1,39,849</b>	<b>102.10</b>

iii. Reconciliation of number of equity shares outstanding at the beginning and at the end of the year

	31 March 2022		31 March 2021	
	Number	Amount	Number	Amount
Equity shares				
Balance at the beginning of the year	1,39,849	102.10	19,563	12.76
Add: Issued during the year			1,20,286	89.34
Balance at the end of the year	<b>1,39,849</b>	<b>102.10</b>	<b>1,39,849</b>	<b>102.10</b>

9. Other equity

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
<b>Reserve and surplus</b>				
Securities premium reserve	53,79,616.00	5,080.57	68,65,042.00	5,080.57
Reserve and surplus	(3,33,613.28)	(1,390.24)	(5,66,898.76)	(459.29)
<b>Total Reserve and surplus</b>	<b>50,46,002.72</b>	<b>3,690.33</b>	<b>62,98,143.24</b>	<b>4,621.28</b>
Foreign Currency translation reserve	-	206.87	-	18.40
	-	<b>206.87</b>	-	<b>18.40</b>
	<b>50,46,002.72</b>	<b>3,897.20</b>	<b>62,98,143.24</b>	<b>4,639.68</b>

Nature and purpose of reserves

Securities premium reserve

The amount received in excess of face value of the equity shares is recognised in Securities Premium Reserve. In case of equity-settled share based payment transactions,

Retained earnings

Retained earnings are the profits that the Company has earned till date, less any transfers to general reserve, dividends or other distributions paid to shareholders.

Lease liability

	As at 31 March 2022		As at 31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
ROU Liability			5,55,679.55	406.26
Other Lease Liability	84,69,723.14	6,419.41	4,59,916.81	336.25
	<b>84,69,723.14</b>	<b>6,419.41</b>	<b>10,15,596.36</b>	<b>742.50</b>

10. Other financial liabilities

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
<b>Current</b>				
Employee related payables	-	-	6,44,284.82	471.04
Rent Payable	-	-	1,82,613.50	133.51
Provision for expenses	15,586.45	11.81	14,400.00	10.52
	<b>15,586.45</b>	<b>11.81</b>	<b>8,41,298.32</b>	<b>615.07</b>



*Handwritten signature*

11. Other liabilities

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
<b>Current</b>				
Advance from customers	21,40,206.95	1,576.85	4,97,265.81	363.55
Advance from Other customer	-	-	-	-
Payable to statutory authorities	1,17,089.06	88.75	97,176.68	71.05
	<b>22,57,296.01</b>	<b>1,665.60</b>	<b>5,94,442.49</b>	<b>434.60</b>

12. Trade payables

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
Dues to micro and small enterprises	-	-	-	-
Others	15,40,155.11	1,167.32	5,43,336.68	397.23
	<b>15,40,155.11</b>	<b>1,167.32</b>	<b>5,43,336.68</b>	<b>397.23</b>

For the year ended March 31, 2022

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years		
(i). MSME	-	-	-	-	-	-
(ii) Others	1,132.87	6.12	-	-	22.54	1,161.53
(iii). Disputed Dues - MSME	-	-	-	-	-	-
(iv). Disputed Dues - Others	-	-	-	-	-	-
(v). Unbilled Dues	-	-	-	-	-	-
<b>Total</b>	<b>1,132.87</b>	<b>6.12</b>	<b>-</b>	<b>-</b>	<b>22.54</b>	<b>1,161.53</b>

For the year ended March 31, 2021

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years		
(i). MSME	-	-	-	-	-	-
(ii) Others	363.02	12.29	-	-	21.93	397.23
(iii). Disputed Dues - MSME	-	-	-	-	-	-
(iv). Disputed Dues - Others	-	-	-	-	-	-
(v). Unbilled Dues	-	-	-	-	-	-
<b>Total</b>	<b>363.02</b>	<b>12.29</b>	<b>-</b>	<b>-</b>	<b>21.93</b>	<b>397.23</b>

13. Income tax liabilities (net)

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
Provision for income tax	-	-	-	-
	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

Refer Note 16 for details of income tax expense



*S. N. Krishna*

## 14 Revenue from operations

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
<b>Sale of services</b>				
Revenues	99,83,445.94	7,440.70	72,03,101.06	5,346.64
	<b>99,83,445.94</b>	<b>7,440.70</b>	<b>72,03,101.06</b>	<b>5,346.64</b>

## 15 Cost of materials consumed

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
Raw material and packing material at the beginning of the year	4,13,006.50	306.56	1,46,774.55	108.95
Add: Purchases during the year	16,65,876.47	1,243.97	6,09,283.67	452.25
Less: Raw material and packing material at the end of the year	1,26,767.10	96.08	4,13,006.50	306.56
	<b>19,52,115.87</b>	<b>1,454.45</b>	<b>3,43,051.72</b>	<b>254.64</b>

## 16 Employee benefits expense

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
Salaries, wages and bonus	49,78,900.16	3,709.59	37,46,699.25	2,781.06
Staff welfare expenses	30,922.26	23.04	22,111.80	16.41
	<b>50,09,822.42</b>	<b>3,732.63</b>	<b>37,68,811.05</b>	<b>2,797.47</b>

## 17. Depreciation and amortisation expense

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
Depreciation of property, plant & equipment (refer note 3)	3,49,316.34	260.26	50,447.33	37.45
Depreciation on right-of-use assets (refer note 4)	10,25,198.49	763.84	9,11,614.94	676.66
Amortisation of intangible assets (refer note 5)	42,150.42	31.40	88,851.95	65.95
	<b>14,16,665.25</b>	<b>1,055.50</b>	<b>10,50,914.22</b>	<b>780.06</b>

## 18 Other expenses

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
Rent	1,04,339.49	77.74	71,379.34	52.98
Repairs and maintenance				
- Buildings		-		-
- Plant and equipment		-		-
- Others	1,49,746.41	111.57	1,26,926.35	94.21
Insurance	7,85,393.36	585.17	4,43,034.92	328.85
Rates and taxes	-	-	351.00	0.26
Outside contract cost	7,29,530.00	543.29	1,88,199.00	139.69
Communication expenses	74,853.81	55.77	89,693.95	66.58
Office maintenance and other expenses	67,873.89	50.57	14,767.36	10.96
Legal and professional fees	4,47,659.11	333.53	15,59,709.00	1,157.72
Bank charges	15,781.63	11.76	5,952.75	4.42
Sales promotion expenses including sales commission	3,31,013.35	246.63	77,035.86	57.18
Membership and subscription	1,08,270.10	80.67	69,751.26	51.77
Miscellaneous expenses	17,046.25	12.70	12,937.16	9.60
	<b>28,31,507.40</b>	<b>2,109.39</b>	<b>26,59,737.95</b>	<b>1,974.24</b>

## 19 Income tax

	31 March 2022		31 March 2021	
	USD	INR (Lakhs)	USD	INR (Lakhs)
<b>Tax expense comprises of:</b>				
Current income tax	(4,39,941.27)	(327.09)	(1,96,522.45)	(145.87)
<b>Income tax expense reported in the statement of profit or loss</b>	<b>(4,39,941.27)</b>	<b>(327.09)</b>	<b>(1,96,522.45)</b>	<b>(145.87)</b>



*Handwritten signature*

## 1. Significant Accounting policies

The following are significant accounting policies of Sai Life Sciences Inc., Wholly owned subsidiary company of Sai Life Sciences Limited, Plot No. DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal-Malkajiri District-500078, Telangana.

### a Basis of Preparation

The Ind AS financial statements have been prepared on the basis of going concern, under the historical cost convention.

### Use of estimates

- b Preparation of the Ind AS financial statements in conformity with generally accepted accounting principles requires the management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent liabilities as at the date of financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from those estimates.

### Revenue Recognition

- c Revenue is recognised to the extent it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.  
Revenue for the services rendered is recognised as services are performed on "cost plus mark up" in accordance with the terms of the arrangement with the respective parties for consulting income.

### Foreign Currency Transaction


- d Transactions in foreign currency are recorded on the basis of monthly average rates prevailing during the month in which the transaction is made (which approximate the exchange rates prevailing on the date of transaction). Monetary assets and liabilities denominated in foreign currency are translated at the rate of exchange at the balance sheet date and resultant gain or loss is recognised in the balance sheet.

## 2. Notes forming part of Ind AS Financial Statements

- a The Company is a 100 % wholly owned Subsidiary company of M/s Sai Life Sciences Limited, India  
b There is no Cash in Hand Balance in the Company as on the Balance Sheet date.  
c The Company holds US \$ 223,996.25/- with citi Bank and \$ 648186.87 with HSBC  
d For Balance Sheet items are recorded at the prevailing rate of INR 75.7925 per US \$ and for Statement of Profit & Loss items INR 74.51 per US \$ is adopted.  
e The Ind AS Financial Statements are verified and signed by us for the purpose of Consolidation of Ind AS Financial Statements of the Parent Company as required by the Board of Directors of the Parent Company M/s Sai Life Sciences Ltd, India

For SIVA KRISHNA & NARAYAN  
Chartered Accountants  
Firm's Registration Number: 003883S

R.V.N. SASTRY  
Partner  
Membership No.: 206635  
Place: Hyderabad  
Date: 12 August, 2022



for and on behalf of Board of Directors of  
Sai Life Sciences Inc

Krishna Raju  
Director

Place: Hyderabad  
Date: 12 August, 2022